HomeCompareATRS vs PLD

ATRS vs PLD: Dividend Comparison 2026

ATRS yields 35.78% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $6.32M in total portfolio value· pulled ahead in Year 7
10 years
ATRS
ATRS
● Live price
35.78%
Share price
$5.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$183.7K
Annual income
$28,272.37
Full ATRS calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — ATRS vs PLD

📍 PLD pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATRSPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATRS + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATRS pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATRS
Annual income on $10K today (after 15% tax)
$3,041.14/yr
After 10yr DRIP, annual income (after tax)
$24,031.51/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $4,443,939.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATRS + PLD for your $10,000?

ATRS: 50%PLD: 50%
100% PLD50/50100% ATRS
Portfolio after 10yr
$3.34M
Annual income
$2,642,354.27/yr
Blended yield
79.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ATRS
No analyst data
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATRS buys
0
PLD buys
0
No recent congressional trades found for ATRS or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATRSPLD
Forward yield35.78%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$183.7K$6.50M
Annual income after 10y$28,272.37$5,256,436.18
Total dividends collected$133.5K$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ATRS vs PLD ($10,000, DRIP)

YearATRS PortfolioATRS Income/yrPLD PortfolioPLD Income/yrGap
1$14,278$3,577.82$11,255$555.24+$3.0KATRS
2$20,051$4,774.15$13,062$1,018.59+$7.0KATRS
3$27,721$6,266.08$15,903$1,926.67+$11.8KATRS
4$37,758$8,096.12$20,839$3,823.32+$16.9KATRS
5$50,707$10,305.96$30,464$8,166.08+$20.2KATRS
6$67,191$12,934.95$52,054$19,457.30+$15.1KATRS
7← crossover$87,913$16,018.70$109,886$54,188.93$22.0KPLD
8$113,655$19,587.81$304,030$186,451.18$190.4KPLD
9$145,277$23,666.62$1,166,125$840,813.32$1.02MPLD
10$183,719$28,272.37$6,504,190$5,256,436.18$6.32MPLD

ATRS vs PLD: Complete Analysis 2026

ATRSStock

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.

Full ATRS Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ATRS vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATRS vs SCHDATRS vs JEPIATRS vs OATRS vs KOATRS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.